- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
WWTR1 Antibody / Hippo Pathway Effector Antibody recognizes WW domain-containing transcription regulator 1 (WWTR1), more commonly known as TAZ, a transcriptional coactivator that serves as one of the principal downstream effectors of the Hippo signaling pathway. Unlike the mitochondrial protein Tafazzin, which is also abbreviated TAZ, WWTR1 regulates gene expression by interacting with TEAD and other transcription factors rather than binding DNA directly. Hippo pathway activation suppresses WWTR1 activity through phosphorylation and cytoplasmic retention, whereas Hippo pathway inhibition permits WWTR1 nuclear translocation and activation of genes controlling cell proliferation, differentiation, tissue regeneration, and stem cell maintenance. Consequently, WWTR1 Antibody / Hippo Pathway Effector Antibody is widely used to investigate Hippo signaling, mechanotransduction, and transcriptional regulation.
WWTR1 functions together with its closely related paralog YAP1 to integrate mechanical, biochemical, and cell polarity signals into transcriptional responses that regulate organ growth and tissue homeostasis. Following nuclear localization, WWTR1 associates primarily with TEAD transcription factors to activate genes involved in cell survival, proliferation, epithelial-to-mesenchymal transition, extracellular matrix remodeling, and cellular plasticity. Through these activities, WWTR1 contributes to embryonic development, wound healing, stem cell self-renewal, and normal tissue regeneration while responding dynamically to changes in cell density and extracellular matrix stiffness.
Aberrant WWTR1 signaling has been implicated in numerous human cancers, including breast, liver, lung, colorectal, pancreatic, and ovarian malignancies, where increased nuclear WWTR1 activity promotes tumor growth, invasion, metastasis, therapeutic resistance, and cancer stem cell phenotypes. Altered Hippo pathway regulation has also been associated with tissue fibrosis, cardiovascular disease, and regenerative disorders. Because WWTR1 occupies a central position downstream of Hippo pathway signaling, it has emerged as an important biomarker and therapeutic target for studies of oncogenic signaling, mechanobiology, regenerative medicine, and targeted cancer therapy.
NSJ Bioreagents' WWTR1 Antibody / Hippo Pathway Effector Antibody supports investigations into Hippo signaling, transcriptional regulation, mechanotransduction, stem cell biology, epithelial-to-mesenchymal transition, tissue regeneration, and cancer progression. Reliable detection of WWTR1 enables researchers to study one of the key transcriptional regulators controlling cell fate decisions, organ size, and cellular responses to mechanical and environmental cues.
Explore additional antibodies involved in Hippo signaling, tumor progression, and epithelial-to-mesenchymal transition on our Cancer Antibodies page.
Optimal dilution of the WWTR1 Antibody / Hippo Pathway Effector Antibody should be determined by the researcher.
A synthetic partial protein derived from human WW domain-containing transcription regulator 1 protein (amino acids Q197-L400) was used as the immunogen for the WWTR1 Antibody.
WWTR1 Antibody is stable at -20oC for one year from date of receipt. After reconstitution, at 4oC for one month. It can also be aliquoted and stored frozen at -20oC for six months. Avoid repeated freeze-thaw cycles.
WWTR1 antibody, TAZ antibody, Transcriptional Coactivator with PDZ-Binding Motif antibody, WW Domain Containing Transcription Regulator 1 antibody, Protein TAZ antibody, Hippo Pathway Effector TAZ antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.